Search company, investor...


Founded Year



Dead | Dead

Total Raised


About Aerovance

Aerovance is a biopharmaceutical company focused on the development and commercialization of clinical-stage products for respiratory and allergic diseases. Aerovance's lead programs are in development for the treatment of uncontrolled asthma and uncontrolled eczema. The company is also developing programs for cystic fibrosis and chronic obstructive pulmonary disease. Aerovance was spun off from Bayer Healthcare's biotechnology unit in August 2004.

Headquarters Location

2929 Seventh Street Suite 120

Berkeley, California, 94710,

United States


Missing: Aerovance's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Aerovance's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Aerovance Patents

Aerovance has filed 3 patents.

patents chart

Application Date

Grant Date


Related Topics




Immunology, Interleukins, Transcription factors, Immune system, Monoclonal antibodies


Application Date


Grant Date



Related Topics

Immunology, Interleukins, Transcription factors, Immune system, Monoclonal antibodies



Aerovance Frequently Asked Questions (FAQ)

  • When was Aerovance founded?

    Aerovance was founded in 2004.

  • Where is Aerovance's headquarters?

    Aerovance's headquarters is located at 2929 Seventh Street, Berkeley.

  • What is Aerovance's latest funding round?

    Aerovance's latest funding round is Dead.

  • How much did Aerovance raise?

    Aerovance raised a total of $150.5M.

  • Who are the investors of Aerovance?

    Investors of Aerovance include Apax Partners, NGN Capital, Lehman Brothers, Clarus, Burrill & Company and 7 more.

  • Who are Aerovance's competitors?

    Competitors of Aerovance include Portola Pharmaceuticals, Ocera Therapeutics, Threshold Pharmaceuticals, BioMarck Pharmaceuticals, BrainCells and 12 more.

Compare Aerovance to Competitors

Bikam Pharmaceuticals

BIKAM Pharmaceuticals, Inc. is an early stage biopharmaceutical company focusing upon the discovery and development of small molecule therapeutics for the treatment of ophthalmic diseases and disorders, including retinitis pigmentosa. Worldwide, there are approximately 1.5 million people which suffer from retinitis pigmentosa (RP), a hereditary disease which leads to blindness. As its initial priority, the company is pursuing the discovery of compounds based on a novel mechanism of action identified by the company's founder, Dr. Shalesh Kaushal. BIKAM has an experienced management team with a strong track record in pharmaceutical drug discovery dedicated to expanding these findings and others from the Kaushal lab to create potential therapeutics to prevent blindness.

BioMarck Pharmaceuticals

BioMarck Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and is currently conducting a Phase 2 study of the efficacy of BIO-11006 in COPD patients.

Selectx Pharmaceuticals

SelectX Pharmaceuticals is a biopharmaceutical company that focuses on the discovery and development of small molecule antimicrobials and other therapeutics for unmet medical needs through the application of its Genetic Chemistry platform.

Topigen Pharmaceuticals

Topigen is a biopharmaceutical company developing several new classes of drugs for respiratory disorders based upon its platform technology using DNARNA chemistry. These drugs are focused on inhibiting multiple inflammatory pathways at the cellular site of inflammation using a single drug product. Per the company, this approach has shown promising preclinical results in inhibiting the underlying inflammation associated with many pulmonary conditions such as asthma COPD and allergic rhinitis AR.

Targeted Cell Therapies

Targeted Cell Therapies (TCT) is a Massachusetts-based biopharmaceutical company that is using its powerful technology platform for the development of biotherapeutics for a broad range of human diseases. The technology permits the oral delivery of large molecules, avoiding the usual need for injection. The company's approach uses glucan particles containing nanoplexed nucleic acid (DNA or RNA) payloads encoding therapeutic molecules. Following oral administration, the glucan particles and their payload are rapidly taken up by macrophages in the small intestine. As the macrophages migrate to sites of inflammation or pathology, the payloads are processed by cellular machinery into active therapeutics. TCT believes that its orally administered therapeutics will be more efficacious and safer than the currently available injectables. Targeted Cell Therapies lead compound is for Gaucher Disease, the most common lysosomal storage disorder. Other targets for the company's biotherapeutics include lytic and low bone density conditions and inflammatory disorders.

Affectis Pharmaceuticals

Affectis Pharmaceuticals, fka neuronova, is a biopharmaceutical company developing drugs for the treatment of psychiatric and inflammatory disorders.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.